This article was originally published in the Brand Finance Healthcare 2026.
GPC’s position as one of China’s leading pharmaceutical and healthcare groups reflects its transformation into a diversified, innovation-led enterprise with a growing international presence. Guided by its ambition to “recreate a new Guangyao Group”, the company continues to strengthen its position across pharmaceuticals, healthcare, consumer wellness, and agricultural technology through innovation, digital transformation, and international expansion. Through sustained investment in research and development, brand building, ESG initiatives, and social responsibility programmes, GPC has reinforced its reputation as a trusted healthcare organisation. Looking ahead, the Group remains focused on advancing innovation-led growth and strengthening its standing as a world-class pharmaceutical and healthcare leader.
Each brand has a clear role, allowing us to cover all segments from midscale to luxury, across resorts, urban hotels and branded residences. At the same time, we support owners and investors with flexible and efficient models, offering the full range of contract types to match their strategic needs. GPC, a leading biopharmaceutical enterprise based in Guangzhou, Guangdong Province, has developed into China's foremost pharmaceutical groups and a Fortune Global 500 company.
Its business spans the full medicine and health value chain, including the research, development, production, and sale of modern Traditional Chinese Medicine (TCM), chemical pharmaceuticals, biological pharmaceuticals, natural beverages, diagnostic equipment, and agricultural technology, alongside healthcare and wellness services.
The group’s portfolio includes well-known brands such as Wanglaoji and Baiyunshan, which benefit from strong heritage and broad consumer recognition. Backed by continued investment in innovation and a diversified business model, GPC maintains a prominent position across both domestic and international markets, supporting the steady expansion of its brand value.
At the outset of China’15th Five-Year Plan, development, GPC is advancing a new phase of innovation-led development, underpinned by its strategic ambition to “recreate a new Guangyao Group.”
The Group is implementing a “4+4+X” business structure alongside a “Four Modernisations” transformation focused on modernisation, technologisation, digitalisation, and internationalisation. Its four cornerstone segments comprise modern TCM, chemical pharmaceuticals, pharmaceutical distribution, and natural beverages, while four growth segments, namely bio-innovation, consumer health, diagnostic equipment, and agricultural technology, are positioned to drive future expansion. Additional extended businesses, including asset operations and medical services, further support diversification.
Through continued brand investment and structural transformation, GPC aims to strengthen its competitive positioning and progress towards becoming world-class enterprise. In scientific and technological innovation, GPC is accelerating its shift towards an innovation-driven model. The Group has built a strong talent pipeline, comprising over 400 senior professionals and more than 120 doctors and post-doctoral researchers. It has also engaged leading experts, including Zhong Nanshan, alongside over 30 experts as scientific advisors. GPC has received multiple national accolades, including three National Science and Technology Progress Awards and one National Technology Invention Award, and holds more than 800 authorised invention patents.
Its innovation ecosystem is supported by over 100 research platforms across different levels, including 15 at the national level. Through the advancement of key initiative such as the National Transformation Center, Rare Core Company, and In-hospital Preparation Production Center, GPC is expanding into emerging fields, including cell and gene therapy, radiopharmaceuticals, and in-hospital preparation transformation.
GPC's internationalisation strategy continues to gain momentum, supported by a growing global footprint. The Group has established the first standardised Traditional Chinese Medicine production facility in Macau, alongside a treasury centre and research and development centre in Hong Kong. It also plans to invest CNY1.5 billion to develop an International Intelligent Manufacturing Centre in the Guangdong-Macau In-depth Cooperation Zone in Hengqin.
Through partnerships with enterprises across Saudi Arabia, Vietnam, South Korea, Japan, GPC is expanding its presence in the Middle East and Southeast Asia. The launch of "WALOVI" as the international brand identity for Wanglaoji further supports its efforts to build global recognition and strengthen its position in overseas markets. In fulfilling its social responsibilities, GPC integrates ESG considerations into its long-term corporate development. As of 2025, the Group has continuously carried out public welfare initiatives for the recycling of expired household medicines for 22 consecutive years, recovering over 1,800 tonnes and benefiting more than 700 million people through a nationwide recycling network.
GPC also supports China’s rural revitalisation agenda by leveraging its brand portfolio to drive regional industry development. Initiatives linked to brands such as Ciningji and Lixiaoji, under the Wanglaoji umbrella, have contributed to the growth of the Guizhou Cili and Guangzhou lychee industries. Its subsidiaries, Pangaoshou, Xingqun, and Hutchison Whampoa Guangzhou Baiyunshan, are promoting the development of the Huajuhong industry in western Guangdong, while Hanfang Company is building a high-altitude Ganoderma lucidum cultivation base in Bomi, Tibet.
Caizhilin Pharmaceutical utilises biotechnology, such as fermentation liquid, in school-enterprise cooperation to empower deep processing of agricultural products. In 2025, GPC Baiyunshan, together with Wanglaoji, donated HKD5 million to support disaster relief efforts in Hong Kong, underscoring its ongoing commitment to social responsibility. GPC is guided by its vision to become a world-class, innovation-led pharmaceutical and healthcare group. This strategic direction continues to support sustained brand value growth and reinforces its market position, while underpinning its broader ambition to “recreate a new Guangyao Group.” Through its diversified capabilities and continued investment in innovation, GPC maintains strong momentum across the pharmaceutical and healthcare sectors, supporting its standing among leading global pharmaceutical brands.
